Eprosartan treatment of PC3 cells at 200 µM induced peak LC3-II expression at 96 h, with 11.1-fold increases. In PA-treated human HepG2 cells, Eprosartan at 5–20 μM did not show the restoration of insulin-stimulated phosphorylation of Akt, GSK3β, and FOXO3 observed with azilsartan and candesartan. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Eprosartan and LC3-II expression in PC3 cells
Cell-based study · PC3 cells [1]
PC3 cells were treated with Eprosartan at 200 µM. LC3-II expression peaked at 96 h, with 11.1-fold increases.
Literature-Reported Treatment Conditions
- Treatment concentration
- 200 µM
- Exposure duration
- 0, 24, 48, 72 and 96 h
- Method
- treated
- Reported limits
- Not stated in the sentences used: vehicle, control.
Methods and source locations
Compound reported in the paper: Eprosartan
Evidence for Eprosartan as the mesylate form reported in the paper, not the free base/neutral form supplied as A11121; no salt equivalence, dose conversion or lot validation.
Materials and methods > Untitled > Reagents (S2); Materials and methods > Untitled > Protein extraction and western blotting (S14); Results > Untitled > Autophagy-induced cell death in ARB-treated PC3 cells (S78, S79); Figure 2. legend (S100)
expression of LC3-II: expression of LC3-II — Results > Untitled > Autophagy-induced cell death in ARB-treated PC3 cells (S78, S79)
Eprosartan and insulin-stimulated phosphorylation in HepG2 cells
Cell-based study · human HepG2 cells [2]
HepG2 cells were treated for 16 h with 0.5 mM PA and three concentrations (5–20 μM) of nine FDA-approved ARBs. Azilsartan and candesartan fully restored the insulin-stimulated phosphorylation of Akt, GSK3β, and FOXO3 in PA-treated HepG2 cells, whereas eprosartan did not have those effects.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5–20 μM
- Exposure duration
- for 16 h, followed by treatment with 100 nM insulin for 15 min
- Vehicle
- DMSO
- Co-treatment
- Other interventions in this design: PA 0.5 mM; insulin 100 nM. Compound effect isolated by the comparison: treated with or without 0.5 mM PA and the indicated concentrations of ARBs.
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: Eprosartan
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Angiotensin receptor blockers (ARBs) (S12); Results > Certain ARBs can alleviate insulin resistance in PA-treated HepG2 cells by attenuating lipid accumulation and intracellular Ca2+ overload (S46, S49)
insulin-stimulated phosphorylation of Akt, GSK3β, and FOXO3: insulin-stimulated phosphorylation of Akt, GSK3β, and FOXO3; comparator: 0.5 mM PA — Results > Certain ARBs can alleviate insulin resistance in PA-treated HepG2 cells by attenuating lipid accumulation and intracellular Ca2+ overload (S46, S49)